AI for drug discovery will be driven by biopharma and the rise of Asian tigers, says Insilico CEO
China-based pharmaceutical companies betting big and small biopharma able to quickly innovate will drive the use of AI for drug discovery – a market some analysts predict will reach a valuation of $20bn by 2024.